The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Anti-transforming growth factor (TGF)-beta antibodies inhibit breast cancer cell tumorigenicity and increase mouse spleen natural killer cell activity. Implications for a possible role of tumor cell/host TGF-beta interactions in human breast cancer progression.
Open accessAbstract
TGF-beta effects on angiogenesis, stroma formation, and immune function suggest its possible involvement in tumor progression. This hypothesis was tested using the 2G7 IgG2b, which neutralizes TGF-beta 1, -beta 2, and -beta 3, and the MDA-231 human breast cancer cell line. Inoculation of these cells in athymic mice decreases mouse spleen natural killer (NK) cell activity. Intraperitoneal injections of 2G7 starting 1 d after intraperitoneal inoculation of tumor cells suppressed intraabdominal tumor and lung metastases, whereas the nonneutralizing anti-TGF-beta 12H5 IgG2a had no effect. 2G7 transiently inhibited growth of established MDA-231 subcutaneous tumors. Histologically, both 2G7-treated and control tumors were identical. Intraperitoneal administration of 2G7 resulted in a marked increase in mouse spleen NK cell activity. 2G7 did not inhibit MDA-231 primary tumor or metastases formation, nor did it stimulate NK cell-mediated cytotoxicity in beige NK-deficient nude mice. Finally, serum-free conditioned medium from MDA-231 cells inhibited the NK cell activity of human blood lymphocytes. This inhibition was blocked by the neutralizing anti-TGF-beta 2G7 antibody but not by a nonspecific IgG2. These data support a possible role for tumor cell TGF-beta in the progression of mammary carcinomas by suppressing host immune surveillance.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“One class, exemplified by galunisertib (LY2157299; developed by Eli Lilly) as a well-studied therapeutic291,292 consists of small molecule inhibitors of TGF-β receptor kinases.”
From TGFβ biology in cancer progression and immunotherapy (2021) · cites this paper as [291]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Roberts, A. B., Sporn, M. B., Assoian, R. K., Smith, J. M., Roche, N. S., Wakefield, L. M., Heine, U., Liotta, L. A., Falanga, V., & Kehrl, J. H. (1986) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.83.12.4167 · Cited by 2,867
Kehrl, J. H., Wakefield, L. M., Roberts, A. B., Jakowlew, S. B., Álvarez‐Mon, M., Derynck, R., Sporn, M. B., & Fauci, A. S. (1986) · The Journal of Experimental Medicine · doi:10.1084/jem.163.5.1037 · Cited by 1,581
Knabbe, C., Lippman, M. E., Wakefield, L. M., Flanders, K. C., Kasid, A., Derynck, R., & Dickson, R. B. (1987) · Cell · doi:10.1016/0092-8674(87)90193-0 · Cited by 974
Roberts, A. B., Anzano, M. A., Lamb, L. C., Smith, J. M., & Sporn, M. B. (1981) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.78.9.5339 · Cited by 919
The Transforming Growth Factor-βs
Roberts, A. B., & Sporn, M. B. (1991) · Springer eBooks · doi:10.1007/978-1-4612-3210-0_8 · Cited by 869
Deactivation of macrophages by transforming growth factor-β
Tsunawaki, S., Sporn, M. B., Ding, A. H., & Nathan, C. (1988) · Nature · doi:10.1038/334260a0 · Cited by 862
Stimulation of the chemotactic migration of human fibroblasts by transforming growth factor beta.
Postlethwaite, A. E., Keski-Oja, J., Moses, H. L., & Kang, A. H. (1987) · The Journal of experimental medicine · doi:10.1084/jem.165.1.251 · Cited by 777
Transforming growth factor beta is an important immunomodulatory protein for human B lymphocytes.
Kehrl, J. H., Roberts, A. B., Wakefield, L. M., Jakowlew, S. B., Sporn, M. B., & Fauci, A. S. (1986) · The Journal of Immunology · doi:10.4049/jimmunol.137.12.3855 · Cited by 759
Rook, A. H., Kehrl, J. H., Wakefield, L. M., Roberts, A. B., Sporn, M. B., Burlington, D. B., Lane, H. C., & Fauci, A. S. (1986) · The Journal of Immunology · doi:10.4049/jimmunol.136.10.3916 · Cited by 570
Transforming growth factor production by chemically transformed cells.
Moses, H. L., Branum, E. L., Proper, J. A., & Robinson, R. A. (1981) · PubMed · Cited by 497
Torre‐Amione, G., Beauchamp, R. D., Koeppen, H., Park, B. H., Schreiber, H. W., Moses, H. L., & Rowley, D. A. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.4.1486 · Cited by 403
Welch, D. R., Fabra, À., & Nakajima, M. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.19.7678 · Cited by 389
de Martin, R., Haendler, B., Hofer-Warbinek, R., Gaugitsch, H. W., Wrann, M., Schlüsener, H., SEIFERT, J. ‐., Bodmer, S., Fontana, A., & Hofer, E. (1987) · The EMBO Journal · doi:10.1002/j.1460-2075.1987.tb02700.x · Cited by 384
Growth factors in the regulation of pericellular proteolysis: a review.
Laiho, M., & Keski‐Oja, J. (1989) · PubMed · Cited by 336
Wrann, M., Bodmer, S., de Martin, R., Siepl, C., Hofer-Warbinek, R., Frei, K., Hofer, E., & Fontana, A. (1987) · The EMBO Journal · doi:10.1002/j.1460-2075.1987.tb02411.x · Cited by 332
The Nude Mouse in Experimental and Clinical Research
Kramers, M. T. C. (1979) · Biochemical Society Transactions · doi:10.1042/bst0070817 · Cited by 307
Factor VIII related antigen as an endothelial cell marker in benign and malignant diseases
Sehested, M., & HOU-JENSEN, K. (1981) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/bf00437598 · Cited by 259
Arteaga, C. L., Tandon, A. K., Hoff, D. D. V., & Osborne, C. K. (1988) · PubMed · Cited by 245
Self-citationSteiner, M. S., & Barrack, E. R. (1992) · Molecular Endocrinology · doi:10.1210/mend.6.1.1738367 · Cited by 239
The Nude mouse in experimental and clinical research
Fogh, J., & Giovanella, B. C. (1978) · Academic Press eBooks · Cited by 212
Dickson, R. B., Kasid, A., Huff, K. K., Bates, S. E., Knabbe, C., Bronzert, D. A., Gelmann, E. P., & Lippman, M. E. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.3.837 · Cited by 194
Transforming growth factor-β: possible roles in carcinogenesis
Roberts, A., Thompson, N. L., Heine, U., Flanders, C., & Sporn, M. (1988) · British Journal of Cancer · doi:10.1038/bjc.1988.135 · Cited by 190
Wu, S. P., Theodorescu, D., Kerbel, R. S., Willson, J. K. V., Mulder, K. M., Humphrey, L. E., & Brattain, M. G. (1992) · The Journal of Cell Biology · doi:10.1083/jcb.116.1.187 · Cited by 180
Lucas, C., Bald, L. N., FENDLY, B. M., Mora-Worms, M., Figari, I. S., Patzer, E. J., & Palladino, M. A. (1990) · The Journal of Immunology · doi:10.4049/jimmunol.145.5.1415 · Cited by 164
Self-citationArrick, B. A., Korc, M., & Derynck, R. (1990) · PubMed · Cited by 160
Arrick, B. A., Lopez, A. R., Elfman, F., Ebner, R., Damsky, C. H., & Derynck, R. (1992) · The Journal of Cell Biology · doi:10.1083/jcb.118.3.715 · Cited by 157
Transforming growth factor beta1 in ductal carcinoma in situ and invasive carcinomas of the breast
Walker, R. A., & Dearing, S. J. (1992) · European Journal of Cancer · doi:10.1016/s0959-8049(05)80116-9 · Cited by 151
Arteaga, C. L., Dugger, T. C., Moses, H. L., Hurd, S. D., & Pietenpol, J. A. (1993) · PubMed · Cited by 139
Self-citationWallick, S. C., Figari, I. S., Morris, R. E., Levinson, A. D., & Palladino, M. A. (1990) · The Journal of Experimental Medicine · doi:10.1084/jem.172.6.1777 · Cited by 138
Zugmaier, G., Ennis, B. W., Deschauer, B., Katz, D. A., Knabbe, C., Wilding, G., Daly, P. F., Lippman, M. E., & Dickson, R. B. (1989) · Journal of Cellular Physiology · doi:10.1002/jcp.1041410217 · Cited by 133
Kuppner, M. C., Hamou, M., Bodmer, S., Fontana, A., & de Tribolet, N. (1988) · International Journal of Cancer · doi:10.1002/ijc.2910420416 · Cited by 133
Zugmaier, G., Paik, S., Wilding, G., Knabbe, C., Bano, M., Lupu, R., Deschauer, B., Simpson, S., Dickson, R. B., & Lippman, M. E. (1991) · PubMed · Cited by 121
Keski‐Oja, J., Blasi, F., Leof, E., & Moses, H. L. (1988) · The Journal of Cell Biology · doi:10.1083/jcb.106.2.451 · Cited by 117
Arteaga, C. L., Coffey, R. J., Dugger, T. C., McCutchen, C. M., Moses, H. L., & Lyons, R. M. (1990) · PubMed · Cited by 116
Self-citationZajchowski, D. A., Band, V., Pauzie, N., Tager, A., Stampfer, M. R., & Sager, R. (1988) · PubMed · Cited by 113
Transcripts for transforming growth factors in human breast cancer: clinical correlates
Barrett-Lee, P. J., Travers, M. T., Luqmani, Y. A., & Coombes, R. C. (1990) · British Journal of Cancer · doi:10.1038/bjc.1990.136 · Cited by 104
Daly, R. J., King, R. J. B., & Darbre, P. D. (1990) · Journal of Cellular Biochemistry · doi:10.1002/jcb.240430302 · Cited by 56
King, R. J. B., Wang, D. Y., Daly, R. J., & Darbre, P. D. (1989) · Journal of Steroid Biochemistry · doi:10.1016/0022-4731(89)90073-3 · Cited by 46
Kasid, A., Knabbe, C., & Lippman, M. E. (1987) · PubMed · Cited by 35
Fraker, L. D., Halter, S. A., & Forbes, J. T. (1986) · Cancer Immunology Immunotherapy · doi:10.1007/bf00199858 · Cited by 21
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
TGF-β Signaling in Tumor Suppression and Cancer Progression
Derynck, R., Akhurst, R. J., & Balmain, A. (2001) · Nature Genetics · doi:10.1038/ng1001-117 · Cited by 2,275
Cytostatic and apoptotic actions of TGF-β in homeostasis and cancer
Siegel, P. M., & Massagué, J. (2003) · Nature reviews. Cancer · doi:10.1038/nrc1208 · Cited by 1,626
TGFβ: the molecular Jekyll and Hyde of cancer
Bierie, B., & Moses, H. L. (2006) · Nature reviews. Cancer · doi:10.1038/nrc1926 · Cited by 1,291
TGF-β signaling in health, disease and therapeutics
Deng, Z., Fan, T. T., Chu, X., Tian, H., Zheng, Y., Li, C., & He, J. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01764-w · Cited by 1,360
Cyclosporine induces cancer progression by a cell-autonomous mechanism
Hojo, M., Morimoto, T., Maluccio, M. A., Asano, T., Morimoto, K., Lagman, M., Shimbo, T., & Suthanthiran, M. (1999) · Nature · doi:10.1038/17401 · Cited by 1,148
Metadata
- Authors
- Arteaga, C. L., Hurd, S. D., Winnier, A. R., Johnson, M. D., Fendly, B. M., & Forbes, J. T.
- Affiliations
- Vanderbilt University (US)
- ORCID
- Arteaga, C L
- Venue
- Journal of Clinical Investigation
- Published
- 1993-12-01
- Volume
- 92
- Issue
- 6
- Pages
- 2569-2576
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC288452
- OpenAlex
- W2146839556
- Cited by
- 359
- References
- 40
- Citations by year
- 2026: 2 · 2025: 7 · 2024: 6 · 2023: 3 · 2022: 6 · 2021: 7 · 2020: 5 · 2019: 7 · 2018: 7 · 2017: 10 · 2016: 4 · 2015: 5 · 2014: 6 · 2013: 11 · 2012: 8
- FWCI
- 4.51
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › TGF-β signaling in diseases
- Life Sciences › Immunology and Microbiology › Immunology › Immune Cell Function and Interaction
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- TGF-beta, anti-TGF-beta antibody, breast cancer, natural killer cells, tumor immunosuppression, tumor progression, metastasis, MDA-MB-231 cells, tumor microenvironment, host immune surveillance, tumor-host interaction
- MeSH terms
- Animals, Antibodies, Breast Neoplasms, Cell Division, Collagen, Cytotoxicity, Immunologic, Factor VIII, Female, Humans, Immunoglobulin G, Killer Cells, Natural, Lung Neoplasms, Mice, Nude, Neoplasm Metastasis, Neoplasm Transplantation, Neovascularization, Pathologic, Recombinant Proteins, Spleen, Transplantation, Heterologous, Tumor Cells, Cultured, Transforming Growth Factor beta, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
